Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers

Bone Marrow Transplantation

Volumn 50, Issue 7, 2015, Pages 924-930

  Anandasabapathy, N ^a,b   Breton, G ^a   Hurley, A ^a   Caskey, M ^a   Trumpfheller, C ^a   Sarma, P ^a   Pring, J ^a   Pack, M ^a   Buckley, N ^a   Matei, I ^c   Lyden, D ^c   Green, J ^d   Hawthorne, T ^d   Marsh, H C ^d   Yellin, M ^d   Davis, T ^d   Keler, T ^d   Schlesinger, S J ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d Celldex Therapeutics Inc   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CDX 301; FLT3 LIGAND; UNCLASSIFIED DRUG; CD135 ANTIGEN; FLT3 PROTEIN, HUMAN;

ADULT; ARTICLE; CELL EXPANSION; COMMUNITY ACQUIRED PNEUMONIA; DENDRITIC CELL; DIARRHEA; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; FOLLICULITIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; INJECTION SITE ERYTHEMA; LYMPHADENOPATHY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOCYTE; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; XEROSTOMIA; ADOLESCENT; CLINICAL TRIAL; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PROCEDURES; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

ADOLESCENT; ADULT; DENDRITIC CELLS; FEMALE; FMS-LIKE TYROSINE KINASE 3; HEALTHY VOLUNTEERS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84934819633     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.74     Document Type: Article

References (25)

1. Bertho JM, Chapel A, Loilleux S, Frick J, Aigueperse J, Gorin NC et al. CD135 (Flk2/Flt3) expression by human thymocytes delineates a possible role of FLT3-ligand in T-cell precursor proliferation and differentiation. Scand J Immunol 2000; 52: 53-61.
2. Gabbianelli M, Pelosi E, Montesoro E, Valtieri M, Luchetti L, Samoggia P et al. Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 1995; 86: 1661-1670.
3. Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med 2003; 198: 305-313.
4. Gasparetto C, Gasparetto M, Morse M, Rooney B, Vredenburgh JJ, Long GD et al. Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF. Cytokine 2002; 18: 8-19.
5. Chao N, Litzow MR, Geller RB, Korbling M, Doroshow JH, Fay J et al. Randomized phase II study of FLT3 ligand (MOBIST™) in combination with GM-CSF or G-CSF for mobiilization of peripheral blood progenitor cells in patients with breast cancer. Am Soc Hematol Meeting Abstr 1999; 2954.
6. Stiff PJ, Beveridge RA, Vose J, Fay J, Schuster MW, Geller RB et al. Randomized Phase II study of Flt3 Ligand (MOBIST™) in combination with GM-CSF or G-CSF for mobilization of peripheral blood progenitor cells in patients with lymphoma or ovarian cancer. Am Soc Hematol Meeting Abstr 1999; 2955.
7. Goldberg GL, Zakrzewski JL, Perales MA, van den Brink MR. Clinical strategies to enhance T cell reconstitution. Semin Immunol 2007; 19: 289-296.
8. Sitnicka E, Buza-Vidas N, Larsson S, Nygren JM, Liuba K, Jacobsen SE. Human CD34 + hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 2003; 102: 881-886.
9. Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, Hoek J et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 2000; 96: 878-884.
10. Pulendran B, Banchereau J, Burkeholder S, Kraus E, Guinet E, Chalouni C et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 2000; 165: 566-572.
11. Freedman RS, Vadhan-Raj S, Butts C, Savary C, Melichar B, Verschraegen C et al. Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas. Clin Cancer Res 2003; 9: 5228-5237.
12. Higano CS, Vogelzang NJ, Sosman JA, Feng A, Caron D, Small EJ. Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer. Clin Cancer Res 2004; 10: 1219-1225.
13. Marroquin CE, Westwood JA, Lapointe R, Mixon A, Wunderlich JR, Caron D et al. Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J Immunother 2002; 25: 278-288.
14. Morse MA, Nair S, Fernandez-Casal M, Deng Y, Peter M St, Williams R et al. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol 2000; 18: 3883-3893.
15. Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 2004; 4: 9.
16. Marroquin CE, Westwood JA, Lapointe R, Mixon A, Wunderlich J R, Caron D et al. Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J Immunother 2002; 25: 278-288.
17. Mosca PJ, Hobeika AC, Colling K, Clay TM, Thomas EK, Caron D et al. Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J Leukoc Biol 2002; 72: 546-553.
18. Brossart P, Grunebach F, Stuhler G, Reichardt VL, Mohle R, Kanz L et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood 1998; 92: 4238-4247.
19. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001; 98: 8809-8814.
20. Lyman SD, James L, Johnson L, Brasel K, de Vries P, Escobar SS et al. Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood 1994; 83: 2795-2801.
21. Jacobsen SE, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD. The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. J Exp Med 1995; 181: 1357-1363.
22. He S, Chu J, Vasu S, Deng Y, Yuan S, Zhang J et al. FLT3L and plerixafor combination increases hematopoietic stem cell mobilization and leads to improved transplantation outcome. Biol Blood Marrow Transplant 2014; 20: 309-313.
23. Graddis TJ, Brasel K, Friend D, Srinivasan S, Wee S, Lyman SD et al. Structure-function analysis of FLT3 ligand-FLT3 receptor interactions using a rapid functional screen. J Biol Chem 1998; 273: 17626-17633.
24. Klein O, Ebert LM, Zanker D, Woods K, Tan BS, Fucikova J et al. Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects. Eur J Immunol 2013; 43: 533-539.
25. Pletinckx K, Lutz MB. Dendritic cells generated with Flt3L and exposed to apoptotic cells lack induction of T cell anergy and Foxp3(+) regulatory T cell conversion in vitro. Immunobiology 2014; 219: 230-240.